GlassScriptPhysician profile
Jason Daniel Empson
NPI 1770255283
$1,915.62
in general payments reported to CMS, 2019-2025
13 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.50 · 2023: $1,629 · 2024: $107 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $668 · Honoraria: $625 · Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $667.95 |
| Honoraria | $625.00 |
| Food and Beverage | $581.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $861.83 | 2023-2025 | Jelmyto |
| Teleflex LLC | $716.36 | 2023-2024 | Urolift |
| Tolmar, INC. | $68.21 | 2023-2025 | Jatenzo, Eligard |
| Astellas Pharma US INC | $65.18 | 2022-2024 | Myrbetriq |
| Abbvie INC. | $38.95 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.72 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $26.67 | 2022 | |
| Coloplast Corp | $20.61 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $20.57 | 2023 | Seglentis |
| Progenics Pharmaceuticals, INC. | $19.47 | 2024 | |
| Laborie Medical Technologies Corp. | $15.25 | 2025 | Optilume Urethral Drug Coated Balloon |
| Boston Scientific Corporation | $15.00 | 2024 | Rezum Generator |
| Sumitomo Pharma America, INC. | $14.80 | 2025 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Empson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.